Icecure Medical

ICCM · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00

About ICCM

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Employees
68
Headquarters
CAESAREA, Haifa
Listed
Feb 2, 2011
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

Icecure Medical executives
NameTitleSince
Ron Mayron—2017
Eyal Shamir—2016
Ronen Tsimerman——
Elisabeth Sadka——
Naum Muchnik——
Tlalit Bussi Tel-Tzure——
Yaacov Goldman——
Sharon Levita——
Oded Tamir——
Doron Birger——

Revenue by product and region

Fiscal year ended Dec 31, 2024: $3.29M total revenue

By product

  • Disposables [Member]$1.83M55.5%
  • Systems [Member]$1.36M41.4%
  • Exclusive distribution agreement and other services [Member]$100.00K3.0%

Similar companies

Companies in the same industry as Icecure Medical

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.